Table 4 Flexible parametric survival models comparing de novo DLBCL and transformed lymphomas.

From: A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study

 

RS

 

OS

 

LSS

 

De novo DLBCL

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Unadjusted

Reference

 

Reference

 

Reference

 

Adjusted

Reference

 

Reference

 

Reference

 

t-FL

 Unadjusted

1.26 (1.10–1.44)

0.001

1.12 (0.99–1.26)

0.07

1.23 (1.08–1.41)

0.002

 Adjusteda

1.42 (1.24–1.62)

<0.001

1.35 (1.20–1.53)

<0.001

1.48 (1.30–1.68)

<0.001

t-EMZL

 Unadjusted

1.01 (0.64–1.59)

0.96

0.97 (0.66–1.43)

0.89

0.78 (0.48–1.27)

0.32

 Adjusteda

0.95 (0.61–1.49)

0.83

0.96 (0.65–1.40)

0.82

0.76 (0.47–1.23)

0.27

t-NMZL

 Unadjusted

1.06 (0.70–1.60)

0.78

0.97 (0.68–1.40)

0.89

1.03 (0.69–1.53)

0.90

 Adjusteda

1.24 (0.83–1.85)

0.30

1.20 (0.84–1.73)

0.32

1.25 (0.84–1.86)

0.28

t-SMZL

 Unadjusted

0.98 (0.55–1.74)

0.94

0.90 (0.53–1.51)

0.68

0.72 (0.38–1.37)

0.32

 Adjusteda

0.87 (0.49–1.56)

0.64

0.84 (0.50–1.41)

0.32

0.67 (0.35–1.27)

0.22

t-LPL/WM

 Unadjusted

1.46 (0.89–2.40)

0.14

1.35 (0.86–2.11)

0.19

1.17 (0.69–1.97)

0.56

 Adjusteda

1.65 (1.02–2.67)

0.04

1.47 (0.94–2.29)

0.09

1.32 (0.78–2.22)

0.30

  1. DLBCL diffuse large B-cell lymphoma, t-FL transformed follicular lymphoma, t-EMZL transformed extranodal marginal zone lymphoma, t-NMZL transformed nodal marginal zone lymphoma, t-SMZL transformed splenic marginal zone lymphoma, t-LPL/WM transformed lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia, RS relative survival, OS overall survival, LSS lymphoma-specific survival.
  2. aModels were adjusted for age, sex, race, stage, and presence of B symptoms.
Back to article page